Methods for diagnosing prostatic adenocarcinoma
US5710007A · kind A · utility
Inventors
Key dates
| Filing date | Sep 29, 1995 |
| Grant date | Jan 20, 1998 |
| Priority date | — |
| Expiry date | Sep 29, 2015 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N33/57434
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
The present invention relates to a method for diagnosing prostatic adenocarcinoma (CAP) in a male human patient without requiring a biopsy. The total prostate specific antigen (PSA) level in the blood or serum of the patient is measured. If the patient has a total PSA level of between 2.5 ng/ml and 20.0 ng/ml, then the free PSA level in the blood or serum of the patient is measured. The proportion of free PSA to total PSA is calculated. If this proportion is less than about 7%, then the patient is diagnosed as having CAP. The present method can also be used on patients that have a total PSA of at least 10.1 ng/ml, but have also had a negative prostate biopsy.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.